Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising cancer incidence across the world
3.2.1.2 Ongoing research and development in immunotherapy
3.2.1.3 Favorable regulatory environment
3.2.1.4 Increasing investments and partnerships
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Adverse side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 PD-1
5.3 PD-L1
5.4 CTLA-4
5.5 Other types
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Lung cancer
6.3 Breast cancer
6.4 Bladder cancer
6.5 Melanoma
6.6 Cervical cancer
6.7 Hodgkin lymphoma
6.8 Colorectal cancer
6.9 Other applications
Chapter 7 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals & clinics
7.3 Cancer centers
7.4 Academic and research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca PLC
9.2 BeiGene, Ltd.
9.3 Bristol-Myers Squibb Company
9.4 Eli Lilly and Company
9.5 F. Hoffmann-La Roche Ltd.
9.6 GlaxoSmithKline plc
9.7 Incyte Corporation
9.8 Immutep Limited
9.9 Merck & Co., Inc.
9.10 Regeneron Pharmaceuticals, Inc.
9.11 Sanofi
9.12 Shanghai Junshi Biosciences Co., Ltd.
